# OnCo record triana-biomedicines (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/triana-biomedicines/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "triana-biomedicines" ;
  schema:name "Triana Biomedicines"@en ;
  schema:description "Triana Biomedicines designs molecular glues that make cancer cells destroy their own faulty proteins. Its first drug, TRI-611, removes the ALK fusion protein that drives a subset of lung cancers and has entered human trials."@en ;
  schema:url <https://onco.cc/companies/triana-biomedicines/>, <https://trianabio.com/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://trianabio.com/>, <https://trianabio.com/pipeline>, <https://trianabio.com/press-release-4-6-2022>, <https://trianabio.com/press-release-12032025-1> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/breast-hr-positive/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/> ;
  onco:technologies <https://onco.cc/technologies/protac-degrader/> ;
  onco:targets <https://onco.cc/targets/alk/> ;
  onco:drugs <https://onco.cc/drugs/tri-611/> ;
  onco:trials <https://onco.cc/trials/nct07491497/> .